Posts Tagged drug

JUDGE REVOKES BOND for George Zimmerman – He Raised Too …

Friday, June 1st, 2012 | Permalink

… same day he goes in. Also: Arizona Watermelon juice, cough syrup, Skittles & Trayvon Martin http ://theconservativetreehouse.com/2012/05/24/update-26-part-2-trayvon-martin-shooting-a-year-of-drug-use-culminates-in-predictable-violence/ …. [Erik Scott was a West Point graduate who went on to serve honorably in the Army, get his MBA from Duke and establish a lucrative career in real estate and as a sales rep for a medical device company. He was 38 years old …

More:
JUDGE REVOKES BOND for George Zimmerman – He Raised Too …

LifeScan to integrate OneTouch technology into Insulet OmniPod …

Thursday, February 16th, 2012 | Permalink

Select a Medical Devices sector, ————————, Anesthesia & Respiratory Devices, Cardiovascular Devices, Dental Devices, Diabetes Care Devices, Drug Delivery Devices , Orthopedic Devices, ————————, In Vitro Diagnostics, Diagnostic Imaging …. The report also reviews the competitive landscape and technology offerings. … MDBR Website Usage About us Accessibility Advertise with us Contact us Help Privacy RSS feeds Site map Dining Club …

Follow this link:
LifeScan to integrate OneTouch technology into Insulet OmniPod …

DexCom to integrate CGM technology with Tandem t:slim system …

Friday, February 3rd, 2012 | Permalink

Select a Medical Devices sector, ————————, Anesthesia & Respiratory Devices, Cardiovascular Devices, Dental Devices, Diabetes Care Devices, Drug Delivery Devices , Orthopedic Devices, ————————, In Vitro Diagnostics, Diagnostic Imaging …. The report also reviews the competitive landscape and technology offerings. … MDBR Website Usage About us Accessibility Advertise with us Contact us Help Privacy RSS feeds Site map Dining Club …

Read More:
DexCom to integrate CGM technology with Tandem t:slim system …

Potential of male urinary incontinence treatment in U.S. could be …

Monday, January 2nd, 2012 | Permalink

Uromedica, which develops urinary incontinence treatments, will find out in as soon as a few weeks if its medical device for men is ready for U.S. Food and Drug Administration approval application. The Minnesota medical device company submitted fresh data to the FDA that, if accepted, would be the basis for a premarket approval (PMA) application, CEO Tim Cook said. Uromedica sent the data, which included a … Comments RSS Post a comment. No comments yet.

Read the original:
Potential of male urinary incontinence treatment in U.S. could be …

For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely

Monday, December 19th, 2011 | Permalink

Keryx Biopharmaceuticals (NASDAQ: KERX) is an emerging small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex), under Special Protocol Assessment (SPA) agreements with the FDA. KERX is Aeterna Zentaris ’ partner and licensee for perifosine in the USA, Canada and Mexico. On Tuesday, Seeking Alpha contributor Jeremy Richards of Private Wealth Fund wrote: “Without question, our company believes strongly in AEterna Zentaris’ (AEZS) lead drug candidate and the likelihood of a takeover of the company.” Richards summarized some of his previous points and provided additional, new analysis of the clinical data to support his position. About Perifosine Richards wrote: “The P3 Perifosine, in combination with Xeloda (Capecitabine) X-Pect study of Keryx, is a trial for a drug combination used to treat metastatic colorectal cancer (mCRC). The combination is referred to as PCAP for Perifosine-Capacitabine. This is a very important study because the number of deaths occurring each year as estimated by WHO is 610,000 worldwide, including 142,570 new cases and 51,370 deaths in the U.S. in 2010. The death rate from mCRC is about 17 per 100,000 people annually in the U.S. CRC is the second most common cancer after lung cancer and more lives are lost each year to colorectal cancer than to breast cancer and AIDS combined. More than 60% of cancers are detected in their late stages. Preliminary evidence is that PCAP is the most effective drug combination known for mCRC.” Read the full article on Seeking Alpha.

Read this article:
For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely